FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2744161197> ?p ?o ?g. }

• W2744161197 endingPage "1182" @default.
• W2744161197 startingPage "1174" @default.
• W2744161197 abstract "Immunogenicity and safety of inactivated zoster vaccine (ZVIN) were evaluated in adults with autoimmune disease. Adults with autoimmune disease treated with immunosuppressive therapy (biologic or nonbiologic) were randomized to receive 4 doses of ZVIN, ZVIN containing a higher quantity of antigen, or placebo. To measure varicella-zoster virus (VZV)-specific immune responses using glycoprotein enzyme-linked immunosorbent assay (gpELISA) and interferon-gamma enzyme-linked immunospot (IFN-γ ELISPOT), blood samples were collected at baseline, post-doses 2, 3, and 4. The primary hypothesis was that ZVIN would elicit significant VZV-specific immune responses, measured by gpELISA or ELISPOT, at approximately 28 days post-dose 4. Safety and tolerability was assessed through 28 days post-dose 4. ZVIN elicited a statistically significant VZV-specific immune response approximately 28 days post-dose 4, measured by gpELISA (estimated geometric mean fold rise from baseline [GMFR] = 1.6 [95% confidence interval [CI], 1.4,1.7], P value < .0001) and IFN-γ ELISPOT (estimated GMFR = 2.0 [95% CI, 1.6,2.6], P value < .0001); both results met the prespecified success criterion. Overall, 57% (164/289) of all ZVIN and 21% (13/62) of placebo recipients reported ≥1 injection-site adverse events (AEs), and 52% (149/289) and 47% (29/62) reported ≥1 systemic AEs, respectively. Eight ZVIN and 1 placebo recipients experienced serious AEs, including 2 events (ZVIN group) determined by the investigator to be vaccine related (keratitis; amnesia). Overall frequency of AEs decreased with subsequent doses of vaccine. In adults with autoimmune disease, ZVIN was well tolerated and elicited statistically significant VZV-specific immune responses approximately 28 days post-dose 4, measured by gpELISA and IFN-γ ELISPOT. NCT01527383." @default.
• W2744161197 created "2017-08-17" @default.
• W2744161197 creator A5006526775 @default.
• W2744161197 creator A5008286260 @default.
• W2744161197 creator A5018040730 @default.
• W2744161197 creator A5021767773 @default.
• W2744161197 creator A5028635765 @default.
• W2744161197 creator A5053086172 @default.
• W2744161197 creator A5071302331 @default.
• W2744161197 creator A5080926064 @default.
• W2744161197 creator A5086647439 @default.
• W2744161197 date "2017-08-05" @default.
• W2744161197 modified "2023-09-24" @default.
• W2744161197 title "Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial" @default.
• W2744161197 cites W164385564 @default.
• W2744161197 cites W1835690873 @default.
• W2744161197 cites W1965296466 @default.
• W2744161197 cites W1981815093 @default.
• W2744161197 cites W2000526469 @default.
• W2744161197 cites W2049032649 @default.
• W2744161197 cites W2064809740 @default.
• W2744161197 cites W2072465157 @default.
• W2744161197 cites W2075994714 @default.
• W2744161197 cites W2076206356 @default.
• W2744161197 cites W2086454732 @default.
• W2744161197 cites W2086658590 @default.
• W2744161197 cites W2097885232 @default.
• W2744161197 cites W2115012618 @default.
• W2744161197 cites W2122633654 @default.
• W2744161197 cites W2124998973 @default.
• W2744161197 cites W2131041950 @default.
• W2744161197 cites W2135503970 @default.
• W2744161197 cites W2135544535 @default.
• W2744161197 cites W2149820050 @default.
• W2744161197 cites W2297608701 @default.
• W2744161197 cites W2346467460 @default.
• W2744161197 cites W4211188326 @default.
• W2744161197 doi "https://doi.org/10.1093/cid/cix484" @default.
• W2744161197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29126292" @default.
• W2744161197 hasPublicationYear "2017" @default.
• W2744161197 type Work @default.
• W2744161197 sameAs 2744161197 @default.
• W2744161197 citedByCount "24" @default.
• W2744161197 countsByYear W27441611972018 @default.
• W2744161197 countsByYear W27441611972019 @default.
• W2744161197 countsByYear W27441611972020 @default.
• W2744161197 countsByYear W27441611972021 @default.
• W2744161197 countsByYear W27441611972023 @default.
• W2744161197 crossrefType "journal-article" @default.
• W2744161197 hasAuthorship W2744161197A5006526775 @default.
• W2744161197 hasAuthorship W2744161197A5008286260 @default.
• W2744161197 hasAuthorship W2744161197A5018040730 @default.
• W2744161197 hasAuthorship W2744161197A5021767773 @default.
• W2744161197 hasAuthorship W2744161197A5028635765 @default.
• W2744161197 hasAuthorship W2744161197A5053086172 @default.
• W2744161197 hasAuthorship W2744161197A5071302331 @default.
• W2744161197 hasAuthorship W2744161197A5080926064 @default.
• W2744161197 hasAuthorship W2744161197A5086647439 @default.
• W2744161197 hasBestOaLocation W27441611971 @default.
• W2744161197 hasConcept C126322002 @default.
• W2744161197 hasConcept C142724271 @default.
• W2744161197 hasConcept C197934379 @default.
• W2744161197 hasConcept C203014093 @default.
• W2744161197 hasConcept C204787440 @default.
• W2744161197 hasConcept C2522874641 @default.
• W2744161197 hasConcept C27081682 @default.
• W2744161197 hasConcept C2776090121 @default.
• W2744161197 hasConcept C2776159415 @default.
• W2744161197 hasConcept C2778375690 @default.
• W2744161197 hasConcept C2779053233 @default.
• W2744161197 hasConcept C2780868878 @default.
• W2744161197 hasConcept C71924100 @default.
• W2744161197 hasConcept C8891405 @default.
• W2744161197 hasConcept C90924648 @default.
• W2744161197 hasConceptScore W2744161197C126322002 @default.
• W2744161197 hasConceptScore W2744161197C142724271 @default.
• W2744161197 hasConceptScore W2744161197C197934379 @default.
• W2744161197 hasConceptScore W2744161197C203014093 @default.
• W2744161197 hasConceptScore W2744161197C204787440 @default.
• W2744161197 hasConceptScore W2744161197C2522874641 @default.
• W2744161197 hasConceptScore W2744161197C27081682 @default.
• W2744161197 hasConceptScore W2744161197C2776090121 @default.
• W2744161197 hasConceptScore W2744161197C2776159415 @default.
• W2744161197 hasConceptScore W2744161197C2778375690 @default.
• W2744161197 hasConceptScore W2744161197C2779053233 @default.
• W2744161197 hasConceptScore W2744161197C2780868878 @default.
• W2744161197 hasConceptScore W2744161197C71924100 @default.
• W2744161197 hasConceptScore W2744161197C8891405 @default.
• W2744161197 hasConceptScore W2744161197C90924648 @default.
• W2744161197 hasIssue "7" @default.
• W2744161197 hasLocation W27441611971 @default.
• W2744161197 hasLocation W27441611972 @default.
• W2744161197 hasOpenAccess W2744161197 @default.
• W2744161197 hasPrimaryLocation W27441611971 @default.
• W2744161197 hasRelatedWork W1966047811 @default.
• W2744161197 hasRelatedWork W1968036257 @default.
• W2744161197 hasRelatedWork W2003042623 @default.
• W2744161197 hasRelatedWork W202460821 @default.

• next